Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Optimaliseren van behandeling en follow-up bij plaveiselcelcarcinoom van de vulva
okt 2019 | Gynaecologische oncologie